Israel-based Silenseed, a clinical-stage biopharmaceutical company, has announced that it has signed a Joint Venture Agreement with Guangzhou Sino-Israel Bio-Industry Investment Fund LLP (GIBF). It is understood that the agreement is for the creation of a jointly-owned Chinese subsidiary, Guangzhou Silenseed-China Ltd., and that GIBF will develop, market, and sell Silenseed’s products.
Menu
Menu